ClinicalTrials.gg
Active, not recruitingNCT06978244Updated Jan 27, 2026

A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers

A Phase 1 interventional study of BL1332 ophthalmic solution and BL1332 ophthalmic vehicle in Ocular Pain, sponsored by Bausch & Lomb Incorporated. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Eye Pain with a site in United States — 3 open to participants now, 4 under way, 1 of them phase 3. Eye Pain · United States.

Enrollment
14th of 16
24 · median 70
Started
2025
the only one that year
Phase 1
3 of 17
none open now
Registered
15th of 17
by date
Lead sponsor
1 of 17
Bausch & Lomb Incorporated

Among the 17 studies in Eye Pain with a site in United States, this one is the 14th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 1, and was the 15th registered.

Eye Pain

31 studies on the registry are indexed under Eye Pain; 7 are open to participants now.

Browse Eye Pain studies →

Open to participants now

3 of the 17 studies in Eye Pain with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Eye Pain studies recruiting now, 1 sets no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Eye Pain with a site in United States, or all of them as a file.
02

Study summary

Single-Center, Phase 1 study to assess the ocular and systemic safety and tolerability of ascending concentrations of topical BL1332 ophthalmic solution eye drops compared with BL1332 vehicle in healthy volunteers, identifying the highest tolerated doses (HTDs)

Read the detailed description

To assess the ocular and systemic safety and tolerability of ascending concentrations of topical BL1332 ophthalmic solution eye drops compared with BL1332 vehicle in healthy volunteers, identifying the highest tolerated doses (HTDs)

03

Conditions studied

  • Ocular Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written prior to conduct of any study-related assessment
  2. Male and female subjects ≥18 to ≤50 years of age and in good health, as assessed by the Investigator from past medical history, physical examination, and laboratory tests at Screening
  3. Vital signs assessed in the sitting position after the subject has rested for at least 3 minutes, within the following ranges at Screening and at the Baseline Visit:

    • Oral body temperature ≥35.0°C and ≤37.5°C
    • Systolic blood pressure ≥90 and \<140 mmHg
    • Diastolic blood pressure ≥50 and \<90 mmHg
    • Pulse rate ≥40 and ≤100 bpm
  4. Body weight ≥50 kg
  5. (BMI) between 18.0 and 30.0 kg/m2 [BMI = Body weight (kg) / Height (m)2]
  6. Corrected visual acuity of 20/40 (Snellen) or better in each eye at Screening
  7. Able to communicate well with the Investigator and to understand and comply with the requirements of the study

Exclusion criteria

Exclusion Criteria:

  1. Women of (WOCBP) or non-vasectomized males with partners of childbearing potential are not eligible, unless they are using an effective method of and agree to use an effective method of contraception until at least 30 days after study treatment.

    1. Women are considered of childbearing potential unless they have undergone permanent sterilization (such as hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal occlusion) or have been amenorrheic for ≥12 months without an alternative medical cause.
    2. Effective methods of contraception include systemic hormonal (inhibition of ovulation not primary mode of action) containing progestins only; single barrier male or female condom with or without spermicide or cap; diaphragm; sponge with spermicide; double barrier (male condom combined with one of the barrier methods); or intrauterine device
    3. Women who are pregnant, lactating, or breastfeeding are excluded.
  2. Any medical condition (systemic or ophthalmic) that may, in the opinion of the Investigator and based on the content of the Investigator's Brochure (IB), preclude the safe administration of IP or safe participation in this study
  3. Use of gabapentinoids or opioids within 30 days prior to Screening
  4. Use of topical capsaicin within 30 days prior to Screening
  5. Chronic use (defined as ≥15 days/month for 3 months prior to Screening) of acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs) or anticipated regular (daily) use during the study
  6. Chronic use of medications or dietary supplements (over-the-counter and/or prescription) that have not been stable for ≥14 days prior to Screening or any anticipated change in the chronic medication regimen
  7. Reported use of tobacco products within 3 months prior to Screening and/or urine cotinine level consistent with use of tobacco product (not passive exposure) at Screening
  8. History of use of marijuana/cannabinoid (CBD) or illicit substances including cocaine, heroin, methamphetamine, hallucinogens, or non-prescribed opioids within 3 months prior to Screening
  9. Use of systemic , anticoagulants, or migraine medications such as ergotamine, calcitonin gene-related peptide (CGRP) antagonists within 30 days prior to the Baseline Visit
  10. Use of cytochrome P450 3A4 () or CYP3A5 inhibitors or inducers within 2 weeks prior to the Baseline Visit
  11. History of any ocular surgery or ocular laser intervention within 6 months prior to Screening
  12. History of any chronic eye disease other than refractive error, incipient cataract, strabismic amblyopia, or anisometropic amblyopia. Subjects with a history of acute eye disease (such as infection, corneal abrasion, or allergy) within 6 months prior to Screening may be eligible if the disease is not currently active.
  13. Any currently active ocular condition that requires use of topical eye drops
  14. Contact lens use within 2 weeks prior to Screening and throughout the study
  15. Consumption of alcohol within 48 hours prior to the Baseline Visit and throughout the study
  16. Donation or loss of ≥450 mL of blood within 8 weeks prior to Screening or longer, if required by local regulation
  17. \<11.0 g/dL at Screening
  18. Current or past history of (HIV) disease and/or hepatitis
  19. Past participation in a clinical study within 30 days prior to Screening
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    BL1332 ophthalmic solution (0.06%, 0.15%, and 0.30% concentrations)

    BL1332 ophthalmic solution (0.06%, 0.15%, and 0.30% concentrations) administered as topical ocular drops

    Drug: BL1332 ophthalmic solution

  • Placebo comparator
    BL1332 vehicle

    BL1332 vehicle administered as topical ocular drops

    Drug: BL1332 ophthalmic vehicle

Interventions

  • DrugBL1332 ophthalmic solution

    Both arms taken four times a day for 1 day

  • DrugBL1332 ophthalmic vehicle

    Both arms taken four times a day for 1 day

06

What researchers measure

Primary outcomes

  1. Incidence of DLTs (dose-limiting toxicities)

    To assess the ocular and systemic safety and tolerability of ascending concentrations of topical BL1332 ophthalmic solution eye drops compared with BL1332 vehicle in healthy volunteers, identifying the highest tolerated doses (HTDs)

    Time frame: Approximately 6 months

  2. Incidence of treatment-emergent AEs (TEAEs)

    To assess the ocular and systemic safety and tolerability of ascending concentrations of topical BL1332 ophthalmic solution eye drops compared with BL1332 vehicle in healthy volunteers, identifying the highest tolerated doses (HTDs)

    Time frame: Approximately 6 months

  3. Treatment-emergent changes in systemic and ocular safety assessments

    To assess the ocular and systemic safety and tolerability of ascending concentrations of topical BL1332 ophthalmic solution eye drops compared with BL1332 vehicle in healthy volunteers, identifying the highest tolerated doses (HTDs)

    Time frame: Approximately 6 months

  4. PK profiles and following parameter, where data allow (Cmax)

    To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers

    Time frame: Approximately 6 months

  5. PK profiles and following parameter, where data allow ( Tmax)

    To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers

    Time frame: Approximately 6 months

  6. PK profiles and following parameter, where data allow (Ctau)

    To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers

    Time frame: Approximately 6 months

  7. PK profiles and following parameter, where data allow (Tlast)

    To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers

    Time frame: Approximately 6 months

  8. PK profiles and following parameter, where data allow ( AUClast)

    To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers

    Time frame: Approximately 6 months

  9. PK profiles and following parameter, where data allow (AUCtau)

    To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers

    Time frame: Approximately 6 months

  10. PK profiles and following parameter, where data allow (AUCinf)

    To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers

    Time frame: Approximately 6 months

  11. PK profiles and following parameter, where data allow (ke1)

    To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers

    Time frame: Approximately 6 months

  12. PK profiles and following parameter, where data allow (t1/2)

    To characterize the plasma PK after ocular administration of BL1332 in healthy volunteers

    Time frame: Approximately 6 months

07

Study locations

1 site
  • Site 101
    Fair Lawn, New Jersey 07410, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Nov 2026, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 18, 2025
StartActual
Jul 29, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06978244
Responsible party
Sponsor
First posted
May 18, 2025
Start date
Jul 29, 2025
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Jan 27, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion